The Cochrane Collaboration has released a list of the top drugs and treatments for COPD patients.
The Cochrane review focuses on the drugs and therapies that have been shown to have a better outcome than placebo.
The Cochran Collaboration is a non-profit organization based in the United Kingdom that reviews clinical trials.
The authors of the Cochrane list say it provides an unbiased overview of drugs and treatment options available to people with COPD.COPD is a chronic, inflammatory condition that affects up to 90% of people over the age of 60.
It affects up, but not all, of the organs in the body and can lead to heart failure and death.
The most commonly prescribed drug for COVID-19 is acetaminophen, but it can also be used as a placebo for some patients.
Other treatments include non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, anti-inflammatories and antifungal medications.
Drugs that do not have any known side effects, such as some antibiotics, can also help with symptoms.
Cochrane says it has published this list of top treatments for COID-19 since 2004.
This is not a definitive list, but Cochrane says the data it has on top drugs shows that the results are comparable to those of placebo.
For example, the Cochran list shows that acetaminol has a lower risk of causing death and a better effect on the progression of COVID than placebo, while ibuprofen has a better result than placebo on the COVID symptoms scale and is also a better choice for some conditions, including cough, fever and cold.
A Cochran spokesperson said: “This is an important list to help health professionals and patients make decisions about which treatments and medicines are the best ones for their individual needs.”
It also highlights the different treatments available to COID patients, including those that have not been well-studied.
“For example the list is an overview, but does not give a complete picture of the treatment options that are available to those with COVID.”
We welcome further research into these important issues and look forward to providing information on which treatments are best.
“Topics:diseases-and-disorders,drugs-and.therapeutics,health,health-policy,clinical-trials,healthcare-facilities,cochrane-group,cooper-barron,nsw,australiaFirst posted May 21, 2018 09:46:52Contact Paul Chivers